Next Article in Journal
Emotional Intelligence and Professional Boredom among Nursing Personnel in Greece
Next Article in Special Issue
Defects in MMR Genes as a Seminal Example of Personalized Medicine: From Diagnosis to Therapy
Previous Article in Journal
“My Patients Asked Me If I Owned a Fruit Stand in Town or Something.” Barriers and Facilitators of Personalized Dietary Advice Implemented in a Primary Care Setting
Previous Article in Special Issue
Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity

LAG-3 Expression Predicts Outcome in Stage II Colon Cancer

Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland
Department of Medical Oncology, HFR Fribourg Hospital, 1708 Fribourg, Switzerland
Division of Pathology and Lab Medicine, University of Toronto, Toronto, ON M5G 1X5, Canada
Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21212, USA
Institute of Pathology, University of Bern, 3008 Bern, Switzerland
Author to whom correspondence should be addressed.
Academic Editors: Enrico Mini and Stefania Nobili
J. Pers. Med. 2021, 11(8), 749;
Received: 16 July 2021 / Accepted: 20 July 2021 / Published: 30 July 2021
(This article belongs to the Special Issue Gastrointestinal Cancers and Personalized Medicine)
Introduction: LAG-3 is an inhibitory immune checkpoint molecule that suppresses T cell activation and inflammatory cytokine secretion. T cell density in the tumor microenvironment of colon cancer plays an important role in the host’s immunosurveillance. We therefore hypothesized that LAG-3 expression on tumor-infiltrating lymphocytes (TILs) predicts outcome in patients with stage II colon cancer. Patients and Methods: Immunohistochemical staining for LAG-3 was performed on tissue microarrays (TMAs) of formalin-fixed paraffin-embedded tissue from 142 stage II colon cancer patients. LAG-3 expression was assessed in TILs within both the tumor front and tumor center and scored as either positive or negative. The primary endpoint was disease-free survival (DFS). Results: In patients diagnosed with stage II colon cancer, the presence of LAG-3 expression on TILs was significantly associated with better 5-year DFS (HR 0.34, 95% CI 0.14–0.80, p = 0.009). The effect on DFS was mainly due to LAG-3-positive TILs in the tumor front (HR 0.33, 95% CI 0.13–0.82, p = 0.012). Conclusion: Assessment of LAG-3 might help to predict outcomes in patients with stage II colon cancer and potentially identify those patients who might benefit from adjuvant chemotherapy. Therefore, LAG-3 may serve as a prognostic biomarker in stage II colon cancer. View Full-Text
Keywords: biomarker; LAG-3; immune checkpoint; colon cancer; survival biomarker; LAG-3; immune checkpoint; colon cancer; survival
Show Figures

Figure 1

MDPI and ACS Style

Rhyner Agocs, G.; Assarzadegan, N.; Kirsch, R.; Dawson, H.; Galván, J.A.; Lugli, A.; Zlobec, I.; Berger, M.D. LAG-3 Expression Predicts Outcome in Stage II Colon Cancer. J. Pers. Med. 2021, 11, 749.

AMA Style

Rhyner Agocs G, Assarzadegan N, Kirsch R, Dawson H, Galván JA, Lugli A, Zlobec I, Berger MD. LAG-3 Expression Predicts Outcome in Stage II Colon Cancer. Journal of Personalized Medicine. 2021; 11(8):749.

Chicago/Turabian Style

Rhyner Agocs, Gaëlle, Naziheh Assarzadegan, Richard Kirsch, Heather Dawson, José A. Galván, Alessandro Lugli, Inti Zlobec, and Martin D. Berger. 2021. "LAG-3 Expression Predicts Outcome in Stage II Colon Cancer" Journal of Personalized Medicine 11, no. 8: 749.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop